DOI . ORG {}

Matching Content Categories {📚}

• Education
• Science
• Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don't see any clear sign of profit-making.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

galunisertib, patients, phase, radiochemotherapy, treatment, article, study, cancer, google, scholar, pubmed, cell, fig, arm, months, cas, online, resource, supplemental, tgfβ, day, inhibitor, receptor, baseline, cells, clinical, dose, tumor, combination, safety, radiation, survival, pfs, response, growth, gueorguieva, lahn, glioblastoma, tmz, analysis, data, transforming, glioma, days, kinase, cleverly, tmzrtx, tgfbeta, advanced, grade,

Topics {✒️}

= pair-wise t-test anti-pd-l1 antibody durvalumab post-chemotherapy t-cell recovery transforming growth factor-beta clinical trials phase 1b/2a-tested patients pair-wise t-tests idh1 r132h mutation thirds-mid-phase-cancer-pipeline tgf-beta1 receptor type enzyme-linked immunosorbent assay multi-analyte immunoassay panel article download pdf receptor tgf-β ri unresectable pancreatic cancer tgf-β ri/alk5 heteroaryl-substituted pyrazole inhibitors tgf-beta inhibitors ready grade drug-related teaes compensatory il-7/il-15 response tgf-β kinase receptors phase ib dose-escalation common drug-related teaes blocking tgf-β signaling tgf-β responsive signature transforming growth factor elevated alpha-fetoprotein prior humboldt-universität zu berlin kelun pharmaceutical/klus pharma phase 1b/2a study showed reduced alpha-fetoprotein cd4 + cd25 + cd127-foxp3+ patient-derived tumor xenografts ann louise cleverly neuro-oncology working group anti-cancer therapies brain natriuretic protein receiving research funding tgf-beta receptor major t-cell subsets full access previous pk analyses high-grade gliomas treated privacy choices/manage cookies phase 1b/2a tgf-beta signaling possibly drug related lower grade tumor phase 1b part phase 1b cohort

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
         description:Purpose Galunisertib, a TGF-β inhibitor, has demonstrated antitumor effects in preclinical and radiographic responses in some patients with malignant glioma. This Phase 1b/2a trial investigated the clinical benefit of combining galunisertib with temozolomide-based radiochemotherapy (TMZ/RTX) in patients with newly diagnosed malignant glioma (NCT01220271). Methods This is an open-label, 2-arm Phase 1b/2a study (N = 56) of galunisertib (intermittent dosing: 14 days on/14 days off per cycle of 28 days) in combination with TMZ/RTX (n = 40), versus a control arm (TMZ/RTX, n = 16). The primary objective of Phase 1b was to determine the safe and tolerable Phase 2 dose of galunisertib. The primary objective of Phase 2a was to confirm the tolerability and pharmacodynamic profile of galunisertib with TMZ/RTX, and the secondary objectives included determining the efficacy and pharmacokinetic (PK) profile of galunisertib with TMZ/RTX in patients with glioblastoma. This study also characterized the changes in the major T-cell subsets during TMZ/RTX plus galunisertib treatment. Results In the Phase 2a study, efficacy results for patients treated with galunisertib plus TMZ/RTX or TMZ/RTX were: median overall survival (18.2 vs 17.9 months), median progression-free survival (7.6 vs 11.5 months), and disease control rate (80% [32/40] vs 56% [9/16] patients) respectively. PK profile of galunisertib plus TMZ/RTX regimen was consistent with previously published PK data of galunisertib. The overall safety profile across treatment arms was comparable. Conclusion No differences in efficacy, safety or pharmacokinetic variables were observed between the two treatment arms.
         datePublished:2020-03-05T00:00:00Z
         dateModified:2020-03-05T00:00:00Z
         pageStart:1570
         pageEnd:1579
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s10637-020-00910-9
         keywords:
            Glioblastoma
            Galunisertib
            Radiochemotherapy
            T cells
            Biomarkers
            Oncology
            Pharmacology/Toxicology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-020-00910-9/MediaObjects/10637_2020_910_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-020-00910-9/MediaObjects/10637_2020_910_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-020-00910-9/MediaObjects/10637_2020_910_Fig3_HTML.png
         isPartOf:
            name:Investigational New Drugs
            issn:
               1573-0646
               0167-6997
            volumeNumber:38
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Antje Wick
               affiliation:
                     name:Heidelberg University Medical Center
                     address:
                        name:Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center, Heidelberg University Medical Center, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Annick Desjardins
               affiliation:
                     name:Duke University
                     address:
                        name:The Preston Robert Tisch Brain Tumor Center at Duke, Duke University, Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Cristina Suarez
               affiliation:
                     name:Universitat Autònoma de Barcelona
                     address:
                        name:Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peter Forsyth
               affiliation:
                     name:H. Lee Moffitt Cancer Center and Research Institute
                     address:
                        name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ivelina Gueorguieva
               affiliation:
                     name:Eli Lilly and Company
                     address:
                        name:Eli Lilly and Company, Erl Wood, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tiana Burkholder
               affiliation:
                     name:Eli Lilly and Company
                     address:
                        name:Eli Lilly and Company, Indianapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ann Louise Cleverly
               affiliation:
                     name:Eli Lilly and Company
                     address:
                        name:Eli Lilly and Company, Erl Wood, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shawn T. Estrem
               affiliation:
                     name:Eli Lilly and Company
                     address:
                        name:Eli Lilly and Company, Indianapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shuaicheng Wang
               affiliation:
                     name:BioStat Solutions, Inc
                     address:
                        name:BioStat Solutions, Inc, Frederick, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael M. Lahn
               affiliation:
                     name:Eli Lilly and Company
                     address:
                        name:Eli Lilly and Company, Indianapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Susan C. Guba
               affiliation:
                     name:Eli Lilly and Company
                     address:
                        name:Eli Lilly and Company, Indianapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David Capper
               affiliation:
                     name:Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health
                     address:
                        name:Department of Neuropathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jordi Rodon
               affiliation:
                     name:Universitat Autònoma de Barcelona
                     address:
                        name:Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
                        type:PostalAddress
                     type:Organization
                     name:U. T. M. D. Anderson Cancer Center
                     address:
                        name:Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, U. T. M. D. Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
      description:Purpose Galunisertib, a TGF-β inhibitor, has demonstrated antitumor effects in preclinical and radiographic responses in some patients with malignant glioma. This Phase 1b/2a trial investigated the clinical benefit of combining galunisertib with temozolomide-based radiochemotherapy (TMZ/RTX) in patients with newly diagnosed malignant glioma (NCT01220271). Methods This is an open-label, 2-arm Phase 1b/2a study (N = 56) of galunisertib (intermittent dosing: 14 days on/14 days off per cycle of 28 days) in combination with TMZ/RTX (n = 40), versus a control arm (TMZ/RTX, n = 16). The primary objective of Phase 1b was to determine the safe and tolerable Phase 2 dose of galunisertib. The primary objective of Phase 2a was to confirm the tolerability and pharmacodynamic profile of galunisertib with TMZ/RTX, and the secondary objectives included determining the efficacy and pharmacokinetic (PK) profile of galunisertib with TMZ/RTX in patients with glioblastoma. This study also characterized the changes in the major T-cell subsets during TMZ/RTX plus galunisertib treatment. Results In the Phase 2a study, efficacy results for patients treated with galunisertib plus TMZ/RTX or TMZ/RTX were: median overall survival (18.2 vs 17.9 months), median progression-free survival (7.6 vs 11.5 months), and disease control rate (80% [32/40] vs 56% [9/16] patients) respectively. PK profile of galunisertib plus TMZ/RTX regimen was consistent with previously published PK data of galunisertib. The overall safety profile across treatment arms was comparable. Conclusion No differences in efficacy, safety or pharmacokinetic variables were observed between the two treatment arms.
      datePublished:2020-03-05T00:00:00Z
      dateModified:2020-03-05T00:00:00Z
      pageStart:1570
      pageEnd:1579
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s10637-020-00910-9
      keywords:
         Glioblastoma
         Galunisertib
         Radiochemotherapy
         T cells
         Biomarkers
         Oncology
         Pharmacology/Toxicology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-020-00910-9/MediaObjects/10637_2020_910_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-020-00910-9/MediaObjects/10637_2020_910_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10637-020-00910-9/MediaObjects/10637_2020_910_Fig3_HTML.png
      isPartOf:
         name:Investigational New Drugs
         issn:
            1573-0646
            0167-6997
         volumeNumber:38
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Antje Wick
            affiliation:
                  name:Heidelberg University Medical Center
                  address:
                     name:Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center, Heidelberg University Medical Center, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Annick Desjardins
            affiliation:
                  name:Duke University
                  address:
                     name:The Preston Robert Tisch Brain Tumor Center at Duke, Duke University, Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Cristina Suarez
            affiliation:
                  name:Universitat Autònoma de Barcelona
                  address:
                     name:Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peter Forsyth
            affiliation:
                  name:H. Lee Moffitt Cancer Center and Research Institute
                  address:
                     name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ivelina Gueorguieva
            affiliation:
                  name:Eli Lilly and Company
                  address:
                     name:Eli Lilly and Company, Erl Wood, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tiana Burkholder
            affiliation:
                  name:Eli Lilly and Company
                  address:
                     name:Eli Lilly and Company, Indianapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ann Louise Cleverly
            affiliation:
                  name:Eli Lilly and Company
                  address:
                     name:Eli Lilly and Company, Erl Wood, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shawn T. Estrem
            affiliation:
                  name:Eli Lilly and Company
                  address:
                     name:Eli Lilly and Company, Indianapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shuaicheng Wang
            affiliation:
                  name:BioStat Solutions, Inc
                  address:
                     name:BioStat Solutions, Inc, Frederick, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael M. Lahn
            affiliation:
                  name:Eli Lilly and Company
                  address:
                     name:Eli Lilly and Company, Indianapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Susan C. Guba
            affiliation:
                  name:Eli Lilly and Company
                  address:
                     name:Eli Lilly and Company, Indianapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David Capper
            affiliation:
                  name:Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health
                  address:
                     name:Department of Neuropathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jordi Rodon
            affiliation:
                  name:Universitat Autònoma de Barcelona
                  address:
                     name:Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
                     type:PostalAddress
                  type:Organization
                  name:U. T. M. D. Anderson Cancer Center
                  address:
                     name:Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, U. T. M. D. Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Investigational New Drugs
      issn:
         1573-0646
         0167-6997
      volumeNumber:38
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Heidelberg University Medical Center
      address:
         name:Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center, Heidelberg University Medical Center, Heidelberg, Germany
         type:PostalAddress
      name:Duke University
      address:
         name:The Preston Robert Tisch Brain Tumor Center at Duke, Duke University, Durham, USA
         type:PostalAddress
      name:Universitat Autònoma de Barcelona
      address:
         name:Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
         type:PostalAddress
      name:H. Lee Moffitt Cancer Center and Research Institute
      address:
         name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
         type:PostalAddress
      name:Eli Lilly and Company
      address:
         name:Eli Lilly and Company, Erl Wood, UK
         type:PostalAddress
      name:Eli Lilly and Company
      address:
         name:Eli Lilly and Company, Indianapolis, USA
         type:PostalAddress
      name:Eli Lilly and Company
      address:
         name:Eli Lilly and Company, Erl Wood, UK
         type:PostalAddress
      name:Eli Lilly and Company
      address:
         name:Eli Lilly and Company, Indianapolis, USA
         type:PostalAddress
      name:BioStat Solutions, Inc
      address:
         name:BioStat Solutions, Inc, Frederick, USA
         type:PostalAddress
      name:Eli Lilly and Company
      address:
         name:Eli Lilly and Company, Indianapolis, USA
         type:PostalAddress
      name:Eli Lilly and Company
      address:
         name:Eli Lilly and Company, Indianapolis, USA
         type:PostalAddress
      name:Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health
      address:
         name:Department of Neuropathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
         type:PostalAddress
      name:Universitat Autònoma de Barcelona
      address:
         name:Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
         type:PostalAddress
      name:U. T. M. D. Anderson Cancer Center
      address:
         name:Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, U. T. M. D. Anderson Cancer Center, Houston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Antje Wick
      affiliation:
            name:Heidelberg University Medical Center
            address:
               name:Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center, Heidelberg University Medical Center, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Annick Desjardins
      affiliation:
            name:Duke University
            address:
               name:The Preston Robert Tisch Brain Tumor Center at Duke, Duke University, Durham, USA
               type:PostalAddress
            type:Organization
      name:Cristina Suarez
      affiliation:
            name:Universitat Autònoma de Barcelona
            address:
               name:Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
               type:PostalAddress
            type:Organization
      name:Peter Forsyth
      affiliation:
            name:H. Lee Moffitt Cancer Center and Research Institute
            address:
               name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
               type:PostalAddress
            type:Organization
      name:Ivelina Gueorguieva
      affiliation:
            name:Eli Lilly and Company
            address:
               name:Eli Lilly and Company, Erl Wood, UK
               type:PostalAddress
            type:Organization
      name:Tiana Burkholder
      affiliation:
            name:Eli Lilly and Company
            address:
               name:Eli Lilly and Company, Indianapolis, USA
               type:PostalAddress
            type:Organization
      name:Ann Louise Cleverly
      affiliation:
            name:Eli Lilly and Company
            address:
               name:Eli Lilly and Company, Erl Wood, UK
               type:PostalAddress
            type:Organization
      name:Shawn T. Estrem
      affiliation:
            name:Eli Lilly and Company
            address:
               name:Eli Lilly and Company, Indianapolis, USA
               type:PostalAddress
            type:Organization
      name:Shuaicheng Wang
      affiliation:
            name:BioStat Solutions, Inc
            address:
               name:BioStat Solutions, Inc, Frederick, USA
               type:PostalAddress
            type:Organization
      name:Michael M. Lahn
      affiliation:
            name:Eli Lilly and Company
            address:
               name:Eli Lilly and Company, Indianapolis, USA
               type:PostalAddress
            type:Organization
      name:Susan C. Guba
      affiliation:
            name:Eli Lilly and Company
            address:
               name:Eli Lilly and Company, Indianapolis, USA
               type:PostalAddress
            type:Organization
      name:David Capper
      affiliation:
            name:Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health
            address:
               name:Department of Neuropathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Jordi Rodon
      affiliation:
            name:Universitat Autònoma de Barcelona
            address:
               name:Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
               type:PostalAddress
            type:Organization
            name:U. T. M. D. Anderson Cancer Center
            address:
               name:Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, U. T. M. D. Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center, Heidelberg University Medical Center, Heidelberg, Germany
      name:The Preston Robert Tisch Brain Tumor Center at Duke, Duke University, Durham, USA
      name:Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
      name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
      name:Eli Lilly and Company, Erl Wood, UK
      name:Eli Lilly and Company, Indianapolis, USA
      name:Eli Lilly and Company, Erl Wood, UK
      name:Eli Lilly and Company, Indianapolis, USA
      name:BioStat Solutions, Inc, Frederick, USA
      name:Eli Lilly and Company, Indianapolis, USA
      name:Eli Lilly and Company, Indianapolis, USA
      name:Department of Neuropathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
      name:Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
      name:Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, U. T. M. D. Anderson Cancer Center, Houston, USA

External Links {🔗}(264)

• Discover the revenue of https://link.springer.com/privacystatement
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/#main bring in each month?
• Get to know what's the income of https://link.springer.com
• How much profit is https://idp.springer.com/auth/personal/springernature?redirect_uri=https://link.springer.com/article/10.1007/s10637-020-00910-9 making per month?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/#eds-c-header-nav net monthly?
• How much money does https://link.springer.com/journals/ make?
• How much revenue does https://www.springernature.com/gp/authors bring in?
• Financial intake of https://link.springernature.com/home/
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/#eds-c-header-popup-search pull in?
• Income figures for https://order.springer.com/public/cart
• Earnings of https://link.springer.com/article/10.1007/s10637-020-00910-9/
• Check the income stats for https://link.springer.com/article/10.1007/s10637-020-00910-9/journal/10637
• Get to know what's the income of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research
• Monthly income for https://link.springer.com/article/10.1007/s10637-020-00910-9/#citeas
• Profit of https://link.springer.com/article/10.1007/s10637-020-00910-9/content/pdf/10.1007/s10637-020-00910-9.pdf
• Monthly income for https://link.springer.com/article/10.1007/s10637-020-00910-9/journal/10637/aims-and-scope
• How much does https://submission.nature.com/new-submission/10637/3 bring in each month?
• How much revenue does https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Antje-Wick-Aff1 produce monthly?
• How much profit does https://link.springer.com/article/10.1007/s10637-020-00910-9/#Aff1 make?
• https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Annick-Desjardins-Aff2's revenue stream
• What's the revenue for https://link.springer.com/article/10.1007/s10637-020-00910-9/#Aff2?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Cristina-Suarez-Aff3 generate monthly?
• How profitable is https://link.springer.com/article/10.1007/s10637-020-00910-9/#Aff3?
• https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Peter-Forsyth-Aff4's financial summary
• Check the income stats for https://link.springer.com/article/10.1007/s10637-020-00910-9/#Aff4
• Revenue of https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Ivelina-Gueorguieva-Aff5
• How much profit is https://link.springer.com/article/10.1007/s10637-020-00910-9/#Aff5 making per month?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Tiana-Burkholder-Aff6 pull in?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/#Aff6 bring in each month?
• Income figures for https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Ann_Louise-Cleverly-Aff5
• What's the financial outcome of https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Shawn_T_-Estrem-Aff6?
• Learn how profitable https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Shuaicheng-Wang-Aff7 is on a monthly basis
• Monthly income for https://link.springer.com/article/10.1007/s10637-020-00910-9/#Aff7
• What's the income generated by https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Michael_M_-Lahn-Aff6 each month?
• What's the income of https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Susan_C_-Guba-Aff6?
• https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-David-Capper-Aff8's revenue stream
• How much profit does https://link.springer.com/article/10.1007/s10637-020-00910-9/#Aff8 make?
• How much profit is https://link.springer.com/article/10.1007/s10637-020-00910-9/#auth-Jordi-Rodon-Aff3-Aff9 making per month?
• See how much https://link.springer.com/article/10.1007/s10637-020-00910-9/#Aff9 makes per month
• What's the revenue for https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9/metrics?
• Check the income stats for https://link.springer.com/10.1007/s00280-015-2895-4?fromPaywallRec=false
• https://link.springer.com/10.1007/s00280-017-3313-x?fromPaywallRec=false's financial summary
• How much does https://link.springer.com/10.1038/s41416-018-0246-z?fromPaywallRec=false net monthly?
• How much revenue does https://link.springer.com/article/10.1007/s10637-020-00910-9/subjects/molecularly-targeted-therapy bring in?
• Explore the financials of https://link.springer.com/article/10.1007/s10637-020-00910-9/subjects/phase-0-trials
• What's the revenue for https://link.springer.com/article/10.1007/s10637-020-00910-9/subjects/phase-iv-trials?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/subjects/phase-ii-trials earn?
• What's the financial outcome of https://link.springer.com/article/10.1007/s10637-020-00910-9/subjects/phase-iii-trials?
• How much money does https://link.springer.com/article/10.1007/s10637-020-00910-9/subjects/targeted-therapies make?
• How much money does https://beta.springernature.com/pre-submission?journalId=10637 make?
• How much income does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR1 have?
• https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR2's total income per month
• What's the total monthly financial gain of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR3?
• What are the earnings of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR4?
• Profit of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR5
• What's the income generated by https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR6 each month?
• Financial intake of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR7
• What is the earnings of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR8?
• How much money does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR9 make?
• How much money does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR10 make?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/#ref-CR11 bring in each month?
• Explore the financials of https://link.springer.com/article/10.1007/s10637-020-00910-9/#ref-CR12
• Get to know what's the income of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR13
• What's the financial outcome of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR14?
• What's the monthly income of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR15?
• Discover the revenue of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#MOESM1
• How much profit does http://clinicaltrials.gov make?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR16 pull in monthly?
• What's the financial gain of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR17?
• Revenue of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#Fig1
• Get to know https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#Tab1's earnings
• What's https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9/figures/1's gross income?
• Earnings of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9/tables/1
• https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#Fig2's total income per month
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9/figures/2 pull in?
• Monthly income for https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#Tab2
• How much revenue does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9/tables/2 produce monthly?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#Fig3 rake in every month?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR18 gross monthly?
• How much money does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9/figures/3 make?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR19 net monthly?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR20 bring in each month?
• https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR21 income
• How much profit is https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR22 making per month?
• How much money does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR23 make?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR24 gross monthly?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR25 gross monthly?
• How much cash flow does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR26 have monthly?
• Check the income stats for https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR27
• Revenue of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR28
• https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR29's financial summary
• How much cash flow does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR30 have monthly?
• How much revenue does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR31 generate?
• How much revenue does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR32 bring in?
• https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR33's financial summary
• Profit of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR34
• How much cash flow does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR35 have monthly?
• Revenue of https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR36
• How much revenue does https://link.springer.com/article/10.1007/s10637-020-00910-9/article/10.1007/s10637-020-00910-9#ref-CR37 produce monthly?
• How much does https://braintumor.org/take-action/about-gbm/ earn?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BD2MXit1Wksbk%3D pull in monthly?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15758009 earn?
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Radiotherapy%20plus%20concomitant%20and%20adjuvant%20temozolomide%20for%20glioblastoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa043330&volume=352&issue=10&pages=987-996&publication_year=2005&author=Stupp%2CR&author=Mason%2CWP&author=Bent%2CMJ&author=Weller%2CM&author=Fisher%2CB&author=Taphoorn%2CMJ&author=Belanger%2CK&author=Brandes%2CAA&author=Marosi%2CC&author=Bogdahn%2CU&author=Curschmann%2CJ&author=Janzer%2CRC&author=Ludwin%2CSK&author=Gorlia%2CT&author=Allgeier%2CA&author=Lacombe%2CD&author=Cairncross%2CJG&author=Eisenhauer%2CE&author=Mirimanoff%2CRO
• How much income is https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BD1MXlsVKhs74%3D earning monthly?
• What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19269895 each month?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Effects%20of%20radiotherapy%20with%20concomitant%20and%20adjuvant%20temozolomide%20versus%20radiotherapy%20alone%20on%20survival%20in%20glioblastoma%20in%20a%20randomised%20phase%20III%20study%3A%205-year%20analysis%20of%20the%20EORTC-NCIC%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2809%2970025-7&volume=10&issue=5&pages=459-466&publication_year=2009&author=Stupp%2CR&author=Hegi%2CME&author=Mason%2CWP&author=Bent%2CMJ&author=Taphoorn%2CMJ&author=Janzer%2CRC&author=Ludwin%2CSK&author=Allgeier%2CA&author=Fisher%2CB&author=Belanger%2CK&author=Hau%2CP&author=Brandes%2CAA&author=Gijtenbeek%2CJ&author=Marosi%2CC&author=Vecht%2CCJ&author=Mokhtari%2CK&author=Wesseling%2CP&author=Villa%2CS&author=Eisenhauer%2CE&author=Gorlia%2CT&author=Weller%2CM&author=Lacombe%2CD&author=Cairncross%2CJG&author=Mirimanoff%2CRO bring in?
• How much revenue does https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DyaK38XhslWlsbw%3D produce monthly?
• What's the financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=1958290?
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Modulation%20of%20T-cell%20function%20by%20gliomas&journal=Immunol%20Today&doi=10.1016%2F0167-5699%2891%2990068-5&volume=12&issue=10&pages=370-374&publication_year=1991&author=Roszman%2CT&author=Elliott%2CL&author=Brooks%2CW?
• Get to know https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BD28XitlCqsA%3D%3D's earnings
• http://scholar.google.com/scholar_lookup?&title=Transforming%20growth%20factor-beta%3A%20a%20molecular%20target%20for%20the%20future%20therapy%20of%20glioblastoma&journal=Curr%20Pharm%20Des&doi=10.2174%2F138161206775201901&volume=12&issue=3&pages=341-349&publication_year=2006&author=Wick%2CW&author=Naumann%2CU&author=Weller%2CM's financial summary
• What are the earnings of https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC3cXmtlyntb8%3D?
• What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20153821?
• How much income is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875339 earning monthly?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Roles%20for%20the%20type%20III%20TGF-beta%20receptor%20in%20human%20cancer&journal=Cell%20Signal&doi=10.1016%2Fj.cellsig.2010.01.016&volume=22&issue=8&pages=1163-1174&publication_year=2010&author=Gatza%2CCE&author=Oh%2CSY&author=Blobe%2CGC?
• How much revenue does https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BD3MXnsFKgt7c%3D generate?
• What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11586292?
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=TGF-beta%20signaling%20in%20tumor%20suppression%20and%20cancer%20progression&journal=Nat%20Genet&doi=10.1038%2Fng1001-117&volume=29&issue=2&pages=117-129&publication_year=2001&author=Derynck%2CR&author=Akhurst%2CRJ&author=Balmain%2CA
• How much revenue does https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DyaK1MXivVGm generate?
• What's the income generated by http://scholar.google.com/scholar_lookup?&title=Smads%3A%20transcriptional%20activators%20of%20TGF-beta%20responses&journal=Cell&doi=10.1016%2FS0092-8674%2800%2981696-7&volume=95&issue=6&pages=737-740&publication_year=1998&author=Derynck%2CR&author=Zhang%2CY&author=Feng%2CXH each month?
• Revenue of https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BD3sXkvVekt7o%3D
• How much does http://scholar.google.com/scholar_lookup?&title=Mechanisms%20of%20TGF-beta%20signaling%20from%20cell%20membrane%20to%20the%20nucleus&journal=Cell&doi=10.1016%2FS0092-8674%2803%2900432-X&volume=113&issue=6&pages=685-700&publication_year=2003&author=Shi%2CY&author=Massague%2CJ gross monthly?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BD3sXmtFOlsLw%3D make?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12954047 generate?
• What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Synthesis%20and%20activity%20of%20new%20aryl-%20and%20heteroaryl-substituted%20pyrazole%20inhibitors%20of%20the%20transforming%20growth%20factor-beta%20type%20I%20receptor%20kinase%20domain&journal=J%20Med%20Chem&doi=10.1021%2Fjm0205705&volume=46&issue=19&pages=3953-3956&publication_year=2003&author=Sawyer%2CJS&author=Anderson%2CBD&author=Beight%2CDW&author=Campbell%2CRM&author=Jones%2CML&author=Herron%2CDK&author=Lampe%2CJW&author=McCowan%2CJR&author=McMillen%2CWT&author=Mort%2CN&author=Parsons%2CS&author=Smith%2CEC&author=Vieth%2CM&author=Weir%2CLC&author=Yan%2CL&author=Zhang%2CF&author=Yingling%2CJM?
• How much revenue does https://link.springer.com/doi/10.1007/s13402-014-0210-8 bring in?
• How much money does https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtVWksL4%3D generate?
• Revenue of http://scholar.google.com/scholar_lookup?&title=Anti-tumor%20activity%20of%20the%20TGF-beta%20receptor%20kinase%20inhibitor%20galunisertib%20%28LY2157299%20monohydrate%29%20in%20patient-derived%20tumor%20xenografts&journal=Cell%20Oncol%20%28Dordr%29&doi=10.1007%2Fs13402-014-0210-8&volume=38&issue=2&pages=131-144&publication_year=2015&author=Maier%2CA&author=Peille%2CAL&author=Vuaroqueaux%2CV&author=Lahn%2CM
• How much cash flow does https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC1cXlsVOhu7c%3D have monthly?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Clinical%20development%20of%20galunisertib%20%28LY2157299%20monohydrate%29%2C%20a%20small%20molecule%20inhibitor%20of%20transforming%20growth%20factor-beta%20signaling%20pathway&journal=Drug%20Des%20Dev%20Ther&doi=10.2147%2FDDDT.S86621&volume=9&pages=4479-4499&publication_year=2015&author=Herbertz%2CS&author=Sawyer%2CJS&author=Stauber%2CAJ&author=Gueorguieva%2CI&author=Driscoll%2CKE&author=Estrem%2CST&author=Cleverly%2CAL&author=Desaiah%2CD&author=Guba%2CSC&author=Benhadji%2CKA&author=Slapak%2CCA&author=Lahn%2CMM generate?
• What are the earnings of https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC3MXhsFCmsb%2FN?
• Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22006998
• Profit of http://scholar.google.com/scholar_lookup?&title=Blockade%20of%20TGF-beta%20signaling%20by%20the%20TGFbetaR-I%20kinase%20inhibitor%20LY2109761%20enhances%20radiation%20response%20and%20prolongs%20survival%20in%20glioblastoma&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-11-1212&volume=71&issue=23&pages=7155-7167&publication_year=2011&author=Zhang%2CM&author=Kleber%2CS&author=Rohrich%2CM&author=Timke%2CC&author=Han%2CN&author=Tuettenberg%2CJ&author=Martin-Villalba%2CA&author=Debus%2CJ&author=Peschke%2CP&author=Wirkner%2CU&author=Lahn%2CM&author=Huber%2CPE
• What's the monthly money flow for https://link.springer.com/doi/10.1007/s10637-014-0192-4?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC2cXitFOgu7rJ net monthly?
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Pharmacokinetic%2C%20pharmacodynamic%20and%20biomarker%20evaluation%20of%20transforming%20growth%20factor-beta%20receptor%20I%20kinase%20inhibitor%2C%20galunisertib%2C%20in%20phase%201%20study%20in%20patients%20with%20advanced%20cancer&journal=Investig%20New%20Drugs&doi=10.1007%2Fs10637-014-0192-4&volume=33&issue=2&pages=357-370&publication_year=2015&author=Rodon%2CJ&author=Carducci%2CM&author=Sepulveda-Sanchez%2CJM&author=Azaro%2CA&author=Calvo%2CE&author=Seoane%2CJ&author=Brana%2CI&author=Sicart%2CE&author=Gueorguieva%2CI&author=Cleverly%2CA&author=Pillay%2CNS&author=Desaiah%2CD&author=Estrem%2CST&author=Paz-Ares%2CL&author=Holdhoff%2CM&author=Blakeley%2CJ&author=Lahn%2CMM&author=Baselga%2CJ
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC2MXhvVegu7o%3D pull in?
• How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25424852 earning monthly?
• Find out how much http://scholar.google.com/scholar_lookup?&title=First-in-human%20dose%20study%20of%20the%20novel%20transforming%20growth%20factor-beta%20receptor%20I%20kinase%20inhibitor%20LY2157299%20monohydrate%20in%20patients%20with%20advanced%20cancer%20and%20glioma&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.ccr-14-1380&volume=21&issue=3&pages=553-560&publication_year=2015&author=Rodon%2CJ&author=Carducci%2CMA&author=Sepulveda-Sanchez%2CJM&author=Azaro%2CA&author=Calvo%2CE&author=Seoane%2CJ&author=Brana%2CI&author=Sicart%2CE&author=Gueorguieva%2CI&author=Cleverly%2CAL&author=Pillay%2CNS&author=Desaiah%2CD&author=Estrem%2CST&author=Paz-Ares%2CL&author=Holdhoff%2CM&author=Blakeley%2CJ&author=Lahn%2CMM&author=Baselga%2CJ earns monthly
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20231676 bring in?
• What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Updated%20response%20assessment%20criteria%20for%20high-grade%20gliomas%3A%20response%20assessment%20in%20neuro-oncology%20working%20group&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2009.26.3541&volume=28&issue=11&pages=1963-1972&publication_year=2010&author=Wen%2CPY&author=Macdonald%2CDR&author=Reardon%2CDA&author=Cloughesy%2CTF&author=Sorensen%2CAG&author=Galanis%2CE&author=Degroot%2CJ&author=Wick%2CW&author=Gilbert%2CMR&author=Lassman%2CAB&author=Tsien%2CC&author=Mikkelsen%2CT&author=Wong%2CET&author=Chamberlain%2CMC&author=Stupp%2CR&author=Lamborn%2CKR&author=Vogelbaum%2CMA&author=Bent%2CMJ&author=Chang%2CSM?
• Learn how profitable https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtVajs7fK is on a monthly basis
• How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21737504?
• What are the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156964?
• What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Immunosuppression%20in%20patients%20with%20high-grade%20gliomas%20treated%20with%20radiation%20and%20temozolomide&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-11-0774&volume=17&issue=16&pages=5473-5480&publication_year=2011&author=Grossman%2CSA&author=Ye%2CX&author=Lesser%2CG&author=Sloan%2CA&author=Carraway%2CH&author=Desideri%2CS&author=Piantadosi%2CS&author=Consortium%2CNC?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28263929 generate?
• What's the profit of http://scholar.google.com/scholar_lookup?&title=Secondary%20Glioblastoma%3A%20molecular%20and%20clinical%20factors%20that%20affect%20outcome%20after%20malignant%20progression%20of%20a%20lower%20grade%20tumor&journal=World%20Neurosurg&doi=10.1016%2Fj.wneu.2017.02.104&volume=102&pages=49-55&publication_year=2017&author=Gessler%2CF&author=Zappi%2CJ&author=Konczalla%2CJ&author=Bernstock%2CJD&author=Forster%2CMT&author=Wagner%2CM&author=Mittelbronn%2CM&author=Seifert%2CV&author=Senft%2CC?
• What is the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26010271?
• What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Temozolomide%20induced%20bone%20marrow%20suppression--a%20single%20institution%20outcome%20analysis%20and%20review%20of%20the%20literature&journal=Am%20J%20Hematol&doi=10.1002%2Fajh.24066&volume=90&issue=9&pages=E183-E184&publication_year=2015&author=Kourelis%2CTV&author=Buckner%2CJC&author=Gangat%2CN&author=Patnaik%2CMM?
• Revenue of https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC2cXhvVCitLrP
• http://scholar.google.com/scholar_lookup?&title=Nonclinical%20safety%20evaluation%20of%20a%20transforming%20growth%20factor%20%C3%9F%20receptor%20I%20kinase%20inhibitor%20in%20Fischer%20344%20rats%20and%20beagle%20dogs&journal=J%20Clin%20Toxicol&doi=10.4172%2F2161-0495.196&volume=4&issue=3&pages=1-10&publication_year=2014&author=Stauber%2CAJ&author=Credille%2CKM&author=Truex%2CLL&author=Ehlhardt%2CWJ&author=Young%2CJK's financial summary
• What are the earnings of https://link.springer.com/doi/10.1007/s12012-014-9297-4?
• Revenue of https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC2cXitVKqtr%2FN
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25488804?
• What are the earnings of http://scholar.google.com/scholar_lookup?&title=Cardiac%20safety%20of%20TGF-beta%20receptor%20I%20kinase%20inhibitor%20LY2157299%20monohydrate%20in%20Cancer%20patients%20in%20a%20first-in-human%20dose%20study&journal=Cardiovasc%20Toxicol&doi=10.1007%2Fs12012-014-9297-4&volume=15&issue=4&pages=309-323&publication_year=2015&author=Kovacs%2CRJ&author=Maldonado%2CG&author=Azaro%2CA&author=Fernandez%2CMS&author=Romero%2CFL&author=Sepulveda-Sanchez%2CJM&author=Corretti%2CM&author=Carducci%2CM&author=Dolan%2CM&author=Gueorguieva%2CI&author=Cleverly%2CAL&author=Pillay%2CNS&author=Baselga%2CJ&author=Lahn%2CMM?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24790790 earn?
• How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004618 make?
• How much cash flow does http://scholar.google.com/scholar_lookup?&title=Sustained%20CD4%2B%20T%20cell-driven%20lymphopenia%20without%20a%20compensatory%20IL-7%2FIL-15%20response%20among%20high-grade%20glioma%20patients%20treated%20with%20radiation%20and%20temozolomide&journal=Oncoimmunology&doi=10.4161%2Fonci.27357&volume=3&issue=1&publication_year=2014&author=Ellsworth%2CS&author=Balmanoukian%2CA&author=Kos%2CF&author=Nirschl%2CCJ&author=Nirschl%2CTR&author=Grossman%2CSA&author=Luznik%2CL&author=Drake%2CCG have monthly?
• What's the total monthly financial gain of https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC3MXnvFKktrc%3D?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21339188 generate?
• How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064696 have monthly?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Immune%20modulation%20effects%20of%20concomitant%20temozolomide%20and%20radiation%20therapy%20on%20peripheral%20blood%20mononuclear%20cells%20in%20patients%20with%20glioblastoma%20multiforme&journal=Neuro-Oncology&doi=10.1093%2Fneuonc%2Fnoq204&volume=13&issue=4&pages=393-400&publication_year=2011&author=Fadul%2CCE&author=Fisher%2CJL&author=Gui%2CJ&author=Hampton%2CTH&author=Cote%2CAL&author=Ernstoff%2CMS produce monthly?
• What is the monthly revenue of https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC38XhsVansrvL?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22910319 generate monthly?
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461157
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Post-chemotherapy%20T-cell%20recovery%20is%20a%20marker%20of%20improved%20survival%20in%20patients%20with%20advanced%20thoracic%20malignancies&journal=Br%20J%20Cancer&doi=10.1038%2Fbjc.2012.362&volume=107&issue=7&pages=1107-1115&publication_year=2012&author=McCoy%2CMJ&author=Lake%2CRA&author=Most%2CRG&author=Dick%2CIM&author=Nowak%2CAK?
• Explore the financials of https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC1cXptFGqtA%3D%3D
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26902851
• How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933481 have monthly?
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=A%20phase%20II%20randomized%20study%20of%20galunisertib%20monotherapy%20or%20galunisertib%20plus%20lomustine%20compared%20with%20lomustine%20monotherapy%20in%20patients%20with%20recurrent%20glioblastoma&journal=Neuro-Oncology&doi=10.1093%2Fneuonc%2Fnow009&volume=18&issue=8&pages=1146-1156&publication_year=2016&author=Brandes%2CAA&author=Carpentier%2CAF&author=Kesari%2CS&author=Sepulveda-Sanchez%2CJM&author=Wheeler%2CHR&author=Chinot%2CO&author=Cher%2CL&author=Steinbach%2CJP&author=Capper%2CD&author=Specenier%2CP&author=Rodon%2CJ&author=Cleverly%2CA&author=Smith%2CC&author=Gueorguieva%2CI&author=Miles%2CC&author=Guba%2CSC&author=Desaiah%2CD&author=Lahn%2CMM&author=Wick%2CW?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC28XhsFWlurnF earn?
• How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26045979 earning monthly?
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449428
• How much does http://scholar.google.com/scholar_lookup?&title=TGF-beta%20signaling%20and%20its%20targeting%20for%20glioma%20treatment&journal=Am%20J%20Cancer%20Res&volume=5&issue=3&pages=945-955&publication_year=2015&author=Han%2CJ&author=Alvarez-Breckenridge%2CCA&author=Wang%2CQE&author=Yu%2CJ net monthly?
• Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28197376
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Novel%20TGF-beta%20inhibitors%20ready%20for%20prime%20time%20in%20onco-immunology&journal=Oncoimmunology&doi=10.1080%2F2162402x.2016.1257453&volume=6&issue=1&publication_year=2017&author=Gramont%2CA&author=Faivre%2CS&author=Raymond%2CE generate?
• How much income is http://scholar.google.com/scholar_lookup?&title=A%20phase%20Ib%20dose-escalation%20and%20cohort-expansion%20study%20of%20safety%20and%20activity%20of%20the%20transforming%20growth%20factor%20%28TGF%29%20%CE%B2%20receptor%20I%20kinase%20inhibitor%20galunisertib%20plus%20the%20anti-PD-L1%20antibody%20durvalumab%20in%20metastatic%20pancreatic%20cancer%20%5Babstract%5D&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2019.37.15_suppl.4124&volume=37&issue=15_suppl&pages=4124-4124&publication_year=2019&author=Melisi%2CD&author=Hollebecque%2CA&author=Oh%2CD-Y&author=Calvo%2CE&author=Varghese%2CAM&author=Borazanci%2CEH&author=Mercade%2CTM&author=Simionato%2CF&author=Park%2CJO&author=Bendell%2CJC&author=Faivre%2CSJ&author=Zhao%2CY&author=Gueorguieva%2CI&author=Man%2CM&author=Estrem%2CS&author=Benhadji%2CKA&author=Lanasa%2CM&author=Guba%2CSC&author=Garcia-Carbonero%2CR earning monthly?
• Check the income stats for https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:STN:280:DC%2BB3MzmtlWlsg%3D%3D
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31295152 earn?
• Discover the revenue of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708671
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=A%20phase%202%20study%20of%20Galunisertib%20%28TGF-beta1%20receptor%20type%20I%20inhibitor%29%20and%20Sorafenib%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma&journal=Clin%20Transl%20Gastroenterol&doi=10.14309%2Fctg.0000000000000056&volume=10&issue=7&publication_year=2019&author=Kelley%2CRK&author=Gane%2CE&author=Assenat%2CE&author=Siebler%2CJ&author=Galle%2CPR&author=Merle%2CP&author=Hourmand%2CIO&author=Cleverly%2CA&author=Zhao%2CY&author=Gueorguieva%2CI&author=Lahn%2CM&author=Faivre%2CS&author=Benhadji%2CKA&author=Giannelli%2CG
• How much money does https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvFChtrvI generate?
• Find out how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30318515 earns monthly
• How much revenue does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251034 produce monthly?
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Galunisertib%20plus%20gemcitabine%20vs.%20gemcitabine%20for%20first-line%20treatment%20of%20patients%20with%20unresectable%20pancreatic%20cancer&journal=Br%20J%20Cancer&doi=10.1038%2Fs41416-018-0246-z&volume=119&issue=10&pages=1208-1214&publication_year=2018&author=Melisi%2CD&author=Garcia-Carbonero%2CR&author=Macarulla%2CT&author=Pezet%2CD&author=Deplanque%2CG&author=Fuchs%2CM&author=Trojan%2CJ&author=Oettle%2CH&author=Kozloff%2CM&author=Cleverly%2CA&author=Smith%2CC&author=Estrem%2CST&author=Gueorguieva%2CI&author=Lahn%2CMMF&author=Blunt%2CA&author=Benhadji%2CKA&author=Tabernero%2CJ?
• What's the financial outcome of https://link.springer.com/article/10.1007/s10637-020-00910-9/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsVOktrzL?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30963691 generate monthly?
• http://scholar.google.com/scholar_lookup?&title=Novel%20transforming%20growth%20factor%20beta%20receptor%20I%20kinase%20inhibitor%20galunisertib%20%28LY2157299%29%20in%20advanced%20hepatocellular%20carcinoma&journal=Liver%20Int&doi=10.1111%2Fliv.14113&volume=39&issue=8&pages=1468-1477&publication_year=2019&author=Faivre%2CS&author=Santoro%2CA&author=Kelley%2CRK&author=Gane%2CE&author=Costentin%2CCE&author=Gueorguieva%2CI&author=Smith%2CC&author=Cleverly%2CA&author=Lahn%2CMM&author=Raymond%2CE&author=Benhadji%2CKA&author=Giannelli%2CG income
• How much does https://www.fiercebiotech.com/biotech/lilly-puts-two-thirds-mid-phase-cancer-pipeline-up-for-sale-major-shake-up-r-d-priorities earn?
• Earnings of http://scholar.google.com/scholar_lookup?&title=First-in-human%20phase%201%20dose-escalation%20trial%20of%20the%20potent%20and%20selective%20next%20generation%20transforming%20growth%20factor-%CE%B2%20receptor%20type%201%20%28TGF-%CE%B2R1%29%20inhibitor%20LY3200882%20in%20patients%20with%20advanced%20cancers%20%5Babstract%5D&journal=J%20Immunother%20Cancer&volume=6&issue=Suppl1&publication_year=2018&author=Yap%2CT&author=Baldini%2CC&author=Massard%2CC&author=Gueorguieva%2CI&author=Zhao%2CY&author=Schmidt%2CS&author=Man%2CM&author=Estrem%2CS&author=Benhadji%2CK&author=Vieito%2CM
• Revenue of http://scholar.google.com/scholar_lookup?&title=Association%20of%20TGF-%CE%B2%20responsive%20signature%20with%20anti-tumor%20effect%20of%20vactosertib%2C%20a%20potent%2C%20oral%20TGF-%CE%B2%20receptor%20type%20I%20%28TGFBRI%29%20inhibitor%20in%20patients%20with%20advanced%20solid%20tumors&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2018.36.15_suppl.3031&volume=36&issue=15_suppl&pages=3031-3031&publication_year=2018&author=Keedy%2CVL&author=Bauer%2CTM&author=Clarke%2CJM&author=Hurwitz%2CH&author=Baek%2CI&author=Ha%2CI&author=Ock%2CC-Y&author=Nam%2CSY&author=Kim%2CM&author=Park%2CN&author=Kim%2CJY&author=Kim%2CS-J
• How much revenue does https://clinicaltrials.gov/ct2/show/NCT03631706 generate?
• See how much https://citation-needed.springer.com/v2/references/10.1007/s10637-020-00910-9?format=refman&flavour=references makes per month
• Profit of https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Antje%20Wick
• See how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Antje%20Wick makes per month
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Antje%20Wick%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en rake in every month?
• How much profit is https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Annick%20Desjardins making per month?
• What is the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Annick%20Desjardins?
• Earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Annick%20Desjardins%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Cristina%20Suarez generate monthly?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Cristina%20Suarez make?
• What's the monthly money flow for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Cristina%20Suarez%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What's the income of https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Peter%20Forsyth?
• Get to know what's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Peter%20Forsyth
• Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Peter%20Forsyth%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Monthly income for https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Ivelina%20Gueorguieva
• How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ivelina%20Gueorguieva make?
• What's https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ivelina%20Gueorguieva%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's gross income?
• Get to know https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Tiana%20Burkholder's earnings
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tiana%20Burkholder's total income per month
• How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tiana%20Burkholder%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Ann%20Louise%20Cleverly generate monthly?
• What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ann%20Louise%20Cleverly?
• Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ann%20Louise%20Cleverly%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Shawn%20T.%20Estrem income
• What's the financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shawn%20T.%20Estrem?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shawn%20T.%20Estrem%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en gross monthly?
• What's the profit of https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Shuaicheng%20Wang?
• What's the financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shuaicheng%20Wang?
• What's https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shuaicheng%20Wang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's gross income?
• What's the income generated by https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Michael%20M.%20Lahn each month?
• Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michael%20M.%20Lahn
• What's the monthly income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michael%20M.%20Lahn%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much money does https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Susan%20C.%20Guba generate?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Susan%20C.%20Guba rake in every month?
• How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Susan%20C.%20Guba%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• Earnings of https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=David%20Capper
• What are the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=David%20Capper?
• What is the monthly revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22David%20Capper%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much income does https://link.springer.com/article/10.1007/s10637-020-00910-9/search?sortBy=newestFirst&dc.creator=Jordi%20Rodon have?
• What's the revenue for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jordi%20Rodon?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jordi%20Rodon%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en net monthly?
• What is the earnings of https://link.springer.com/article/10.1007/s10637-020-00910-9/mailto:[email protected]?
• What's the income of https://static-content.springer.com/esm/art%3A10.1007%2Fs10637-020-00910-9/MediaObjects/10637_2020_910_MOESM1_ESM.pdf?
• Profit of http://creativecommons.org/licenses/by/4.0/
• Monthly income for https://s100.copyright.com/AppDispatchServlet?title=Phase%201b%2F2a%20study%20of%20galunisertib%2C%20a%20small%20molecule%20inhibitor%20of%20transforming%20growth%20factor-beta%20receptor%20I%2C%20in%20combination%20with%20standard%20temozolomide-based%20radiochemotherapy%20in%20patients%20with%20newly%20diagnosed%20malignant%20glioma&author=Antje%20Wick%20et%20al&contentID=10.1007%2Fs10637-020-00910-9©right=The%20Author%28s%29&publication=0167-6997&publicationDate=2020-03-05&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY
• Get to know https://crossmark.crossref.org/dialog/?doi=10.1007/s10637-020-00910-9's earnings
• Learn about the earnings of https://citation-needed.springer.com/v2/references/10.1007/s10637-020-00910-9?format=refman&flavour=citation
• How profitable is https://link.springer.com/article/10.1007/s10637-020-00910-9/search?query=Glioblastoma&facet-discipline="Medicine%20%26%20Public%20Health"?
• How much does https://link.springer.com/article/10.1007/s10637-020-00910-9/search?query=Galunisertib&facet-discipline="Medicine%20%26%20Public%20Health" make?
• How much profit does https://link.springer.com/article/10.1007/s10637-020-00910-9/search?query=Radiochemotherapy&facet-discipline="Medicine%20%26%20Public%20Health" make?
• https://link.springer.com/article/10.1007/s10637-020-00910-9/search?query=T%20cells&facet-discipline="Medicine%20%26%20Public%20Health"'s revenue stream
• Revenue of https://link.springer.com/article/10.1007/s10637-020-00910-9/search?query=Biomarkers&facet-discipline="Medicine%20%26%20Public%20Health"
• What's the financial intake of https://link.springer.com/journals/a/1?
• See how much https://link.springer.com/books/a/1 makes per month
• How much does https://link.springer.com/journals pull in monthly?
• What are the total earnings of https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral?
• What's the monthly income of https://www.springernature.com/gp/products?
• Discover the revenue of https://www.springernature.com/gp/librarians
• Get to know https://www.springernature.com/gp/societies's earnings
• How much does https://www.springernature.com/gp/partners bring in each month?
• How profitable is https://www.springer.com/?
• Revenue of https://www.nature.com/
• https://www.biomedcentral.com/ income
• Find out how much https://www.palgrave.com/ earns monthly
• How much revenue does https://www.apress.com/ produce monthly?
• How much revenue does https://link.springer.com/brands/discover produce monthly?
• What is the monthly revenue of https://www.springernature.com/gp/legal/ccpa?
• Monthly income for https://www.springernature.com/gp/info/accessibility
• How much does https://link.springer.com/termsandconditions pull in monthly?
• Learn how profitable https://support.springernature.com/en/support/home is on a monthly basis
• How much cash flow does https://link.springer.com/legal-notice have monthly?
• What are the earnings of https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations?
• Monthly income for https://www.springernature.com/

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

Emails and Hosting {✉️}

Mail Servers:

• mx.zoho.eu
• mx2.zoho.eu
• mx3.zoho.eu

Name Servers:

• josh.ns.cloudflare.com
• zita.ns.cloudflare.com